Tenofovir alafenamide: safer, but questions remain

Affiliations

¹ The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
² The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia.

Comment

Mark A Boyd et al. Lancet HIV. 2016 Apr.

. 2016 Apr;3(4):e148-9.

doi: 10.1016/S2352-3018(16)00039-4. Epub 2016 Mar 14.

¹ The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: mboyd@kirby.unsw.edu.au.
² The Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, NSW 2052, Australia.

No abstract available

Comment on

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS. Gallant JE, et al. Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2. Epub 2016 Mar 14. Lancet HIV. 2016. PMID: 27036991 Clinical Trial.